Project Management in Drug Development Webinar
13 juin 2024 09h30 HE
|
Research and Markets
Dublin, June 13, 2024 (GLOBE NEWSWIRE) -- The "Project Management in Drug Development" training has been added to ResearchAndMarkets.com's offering. Project management is crucial to drug...
GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024: Insight on 15+ Drugs in Clinical Trials
07 juin 2024 03h32 HE
|
Research and Markets
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Global GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. In...
FDA Grants Orphan Drug Designation to Biompharma’s Bi104, a microbiome-modifying biologic, for the treatment of Angelman Syndrome
08 mai 2024 09h25 HE
|
Biom Pharmaceutical Corporation
Sarasota, Florida, May 08, 2024 (GLOBE NEWSWIRE) -- BIOM Pharmaceutical Corporation is thrilled to announce that Bi104, its innovative drug product, has been granted orphan-drug designation by the...
Global CD70 Targeting Therapies Market & Clinical Trials Report 2024 - Insight by Company, Country, Indication & Phase
29 avr. 2024 07h32 HE
|
Research and Markets
Dublin, April 29, 2024 (GLOBE NEWSWIRE) -- The "Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. ...
Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024 - Groundbreaking Advances in PLK Targeted Therapies Promise to Revolutionize Treatment for Cancer and Other Diseases
29 avr. 2024 06h53 HE
|
Research and Markets
Dublin, April 29, 2024 (GLOBE NEWSWIRE) -- The "Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's...
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
16 avr. 2024 08h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its...
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
08 avr. 2024 08h30 HE
|
Longeveron
CEO Letter to Shareholders. Update on overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.
Intelligencia AI Awarded U.S. Patent for Its Accurate and Transparent Probability of Drug Success Assessments
02 avr. 2024 13h43 HE
|
Intelligencia AI
Health tech company pioneers de-risking clinical development through patented algorithms, technology and use of artificial intelligence
Intelligencia AI Ranks No. 90 on Inc. Magazine’s List of the Northeast Region’s Fastest-Growing Private Companies
20 mars 2024 09h18 HE
|
Intelligencia AI
Inc. magazine recently revealed that Intelligencia AI, a provider of AI-powered decision-making solutions for the pharmaceutical industry, ranks No. 90.
Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029: 800+ Bispecific Candidates Currently in Active Clinical Development
18 mars 2024 05h16 HE
|
Research and Markets
Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's...